Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-457-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$105.56 million
Profitability
Miscellaneous
Employees133
Next Earnings Date10/24/2019 (Confirmed)
OptionableOptionable
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) issued its quarterly earnings results on Wednesday, July, 24th. The biotechnology company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.25. The biotechnology company had revenue of $30.42 million for the quarter, compared to the consensus estimate of $27.41 million. Anika Therapeutics had a net margin of 26.87% and a return on equity of 11.27%. Anika Therapeutics's quarterly revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.68 EPS. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
How can I listen to Anika Therapeutics' earnings call?
Anika Therapeutics will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Anika Therapeutics issued on next quarter's earnings?
Anika Therapeutics updated its FY 2019 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $106.61055-109.7772 million, compared to the consensus revenue estimate of $101.89 million.
What price target have analysts set for ANIK?
4 brokerages have issued 1 year price targets for Anika Therapeutics' stock. Their forecasts range from $35.00 to $58.00. On average, they anticipate Anika Therapeutics' stock price to reach $49.00 in the next twelve months. This suggests that the stock has a possible downside of 14.0%. View Analyst Price Targets for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anika Therapeutics.
What are Wall Street analysts saying about Anika Therapeutics stock?
Here are some recent quotes from research analysts about Anika Therapeutics stock:
- 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (9/26/2019)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019)
Has Anika Therapeutics been receiving favorable news coverage?
News articles about ANIK stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Anika Therapeutics earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Anika Therapeutics.
Are investors shorting Anika Therapeutics?
Anika Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 2,250,000 shares, a drop of 9.6% from the August 30th total of 2,490,000 shares. Based on an average daily volume of 201,900 shares, the days-to-cover ratio is currently 11.1 days. Approximately 16.8% of the company's shares are short sold. View Anika Therapeutics' Current Options Chain.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), STAAR Surgical (STAA), Cerus (CERS), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).
What other stocks do shareholders of Anika Therapeutics own?
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
- Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
- Mr. Alexei Goraltchouk, VP of Operations
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Boston Trust Walden Corp (2.70%), Envestnet Asset Management Inc. (0.13%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.08%), State of Alaska Department of Revenue (0.08%), Nisa Investment Advisors LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Anika Therapeutics stock include Charles H Sherwood, Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Richard Hague. View Institutional Ownership Trends for Anika Therapeutics.
Which major investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC and Envestnet Asset Management Inc.. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, Jeffery S Thompson, Joseph L Bower and Raymond J Land. View Insider Buying and Selling for Anika Therapeutics.
Which major investors are buying Anika Therapeutics stock?
ANIK stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Meeder Asset Management Inc., Nisa Investment Advisors LLC and Boston Trust Walden Corp. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $56.98.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $785.12 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.
What is Anika Therapeutics' official website?
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
